Side Effects (Bass book)

Last updated
Side Effects
Side Effects - A Prosecutor, a Whistleblower, and a Bestselling Antidepressant on Trial.jpg
Author Alison Bass
LanguageEnglish
Series1
Subject
GenreNon-fiction
Publisher Algonquin Books of Chapel Hill
Publication date
June 17, 2008
Media typeHardcover
Pages260
ISBN 978-1-565-12553-7
LC Class KF228.S685B37 2008

Side Effects: A Prosecutor, a Whistleblower, and a Bestselling Antidepressant on Trial is a nonfiction book by investigative journalist Alison Bass that chronicles the lawsuit filed in 2004 against GlaxoSmithKline by then New York Attorney General Eliot Spitzer. [1]

Contents

Also examined is how Donna Howard, a former assistant administrator for Brown University’s department of Psychiatry, exposed deception in the research and marketing of Paxil, an antidepressant prescribed to millions of children and adults. [2] The book shows the connections between pharmaceutical giant GlaxoSmithKline (the maker of Paxil), a top Ivy League research institution, and the government agency designed to protect the public – conflicted relationships that may have compromised the health and safety of vulnerable children.

Side Effects also explores the controversy over drugs used to treat clinical depression, with a special focus on Paxil, Prozac and Zoloft. The book provides evidence of medical researchers "skewing results on behalf of pharmaceutical companies" that pay for the studies; pharmaceutical companies "marketing medicines without adequately disclosing adverse impacts;" and government agencies "unable or unwilling to adequately protect consumers," who sometimes die as a result. [3] [4]

Award

Side Effects received the NASW Science in Society Award for 2009. In making the announcement, one of the judges said that Bass's book "led to changes in policy in many areas of public health, not only nationally but internationally." [5]

See also

Related Research Articles

<span class="mw-page-title-main">Pfizer</span> American multinational pharmaceutical and biotechnology corporation

<span class="mw-page-title-main">Paroxetine</span> SSRI antidepressant medication

Paroxetine, sold under the brand names Paxil and Seroxat among others, is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. It is used to treat major depressive disorder, obsessive-compulsive disorder, panic disorder, social anxiety disorder, post-traumatic stress disorder, generalized anxiety disorder, and premenstrual dysphoric disorder. It has also been used in the treatment of premature ejaculation and hot flashes due to menopause. It is taken by mouth.

<span class="mw-page-title-main">Novartis</span> Swiss-American multinational pharmaceutical corporation

Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Consistently ranked in the global top five, Novartis is one of the largest pharmaceutical companies in the world and was the fourth largest by revenue in 2022.

<span class="mw-page-title-main">GSK plc</span> British multinational pharmaceutical and biotechnology company

<span class="mw-page-title-main">Pharmaceutical industry</span> Industry involved with discovery, development, production and marketing of drugs

The pharmaceutical industry discovers, develops, produces, and markets drugs or pharmaceutical drugs for use as medications to be administered to patients, with the aim to cure them, vaccinate them, or alleviate symptoms. Pharmaceutical companies may deal in generic or brand medications and medical devices. They are subject to a variety of laws and regulations that govern the patenting, testing, safety, efficacy using drug testing and marketing of drugs. The global pharmaceuticals market produced treatments worth $1,228.45 billion in 2020 and showed a compound annual growth rate (CAGR) of 1.8%.

<span class="mw-page-title-main">Rosiglitazone</span> Chemical compound

Rosiglitazone is an antidiabetic drug in the thiazolidinedione class. It works as an insulin sensitizer, by binding to the PPAR in fat cells and making the cells more responsive to insulin. It is marketed by the pharmaceutical company GlaxoSmithKline (GSK) as a stand-alone drug or for use in combination with metformin or with glimepiride. First released in 1999, annual sales peaked at approximately $2.5-billion in 2006; however, following a meta-analysis in 2007 that linked the drug's use to an increased risk of heart attack, sales plummeted to just $9.5-million in 2012. The drug's patent expired in 2012.

<span class="mw-page-title-main">Cefuroxime</span> Chemical compound

Cefuroxime, sold under the brand name Zinacef among others, is a second-generation cephalosporin antibiotic used to treat and prevent a number of bacterial infections. These include pneumonia, meningitis, otitis media, sepsis, urinary tract infections, and Lyme disease. It is used by mouth or by injection into a vein or muscle.

<span class="mw-page-title-main">Alosetron</span> Medication

Alosetron, sold under the brand name Lotronex among others, is a 5-HT3 antagonist used for the management of severe diarrhea-predominant irritable bowel syndrome (IBS) in females only.

<span class="mw-page-title-main">ViroPharma</span>

ViroPharma Incorporated was a pharmaceutical company that developed and sold drugs that addressed serious diseases treated by physician specialists and in hospital settings. The company focused on product development activities on viruses and human disease, including those caused by cytomegalovirus (CMV) and hepatitis C virus (HCV) infections. It was purchased by Shire in 2013, with Shire paying around $4.2 billion for the company in a deal that was finalized in January 2014. ViroPharma was a member of the NASDAQ Biotechnology Index and the S&P 600.

<span class="mw-page-title-main">Apotex</span> Canadian pharmaceutical company

Apotex Inc. is a Canadian pharmaceutical corporation. Founded in 1974 by Barry Sherman, the company is the largest producer of generic drugs in Canada, with annual sales exceeding CA$2.5 billion. By 2023, Apotex employed close to 8,000 people as Canada's largest drug manufacturer, with over 300 products selling in over 115 countries. Apotex manufactures and distributes generic medications for a range of diseases and health conditions that include cancer, diabetes, high cholesterol, glaucoma, infections and blood pressure.

<span class="mw-page-title-main">Beecham Group</span> Former British pharmaceutical company (1859–1989)

The Beecham Group plc was a British pharmaceutical company. It was once a constituent of the FTSE 100 Index. Beecham, after having merged with American pharmaceutical company SmithKline Beckman to become SmithKline Beecham, merged with Glaxo Wellcome to become GlaxoSmithKline (GSK). GSK still uses the Beechams brand name in the UK for its over-the-counter cold and flu relief products.

The number of new psychiatric drugs, and especially antidepressants on the market in Japan, is significantly less than Western countries.

The ethics involved within pharmaceutical sales is built from the organizational ethics, which is a matter of system compliance, accountability and culture. Organizational ethics are used when developing the marketing and sales strategy to both the public and the healthcare profession of the strategy. Organizational ethics are best demonstrated through acts of fairness, compassion, integrity, honor, and responsibility.

<span class="mw-page-title-main">Casopitant</span> Chemical compound

Casopitant (INN), former tentative trade names Rezonic (U.S.) and Zunrisa (Europe), is an NK1 receptor antagonist which was undergoing research for the treatment of chemotherapy-induced nausea and vomiting. It was under development by GlaxoSmithKline. In July 2008, the company filed a marketing authorisation application with the European Medicines Agency. The application was withdrawn and development was discontinued in September 2009 because GlaxoSmithKline decided that further safety assessment was necessary. However, a 2022 review listed casopitant as under development as a potential novel antidepressant for the treatment of major depressive disorder, with a phase 2 clinical trial having been completed.

Alison Bass is an American journalist and author of three books: her memoir, Brassy Broad: How one Journalist helped pave the way to #MeToo (2021); Getting Screwed: Sex Workers and the Law and Side Effects: A Prosecutor, A Whistleblower and a Bestselling Antidepressant on Trial.Side Effects won the National Association of Science Writers' Science in Society Award and its film rights were recently optioned.

The pharmaceutical industry in the United Kingdom directly employs around 73,000 people and in 2007 contributed £8.4 billion to the UK's GDP and invested a total of £3.9 billion in research and development. In 2007 exports of pharmaceutical products from the UK totalled £14.6 billion, creating a trade surplus in pharmaceutical products of £4.3 billion.

<span class="mw-page-title-main">Wyeth</span> American pharmaceutical company

Wyeth was a pharmaceutical company until it was purchased by Pfizer in 2009. The company was founded in Philadelphia, Pennsylvania, in 1860 as John Wyeth and Brother. Its headquarters moved to Collegeville, Pennsylvania, and Madison, New Jersey, before its headquarters were consolidated with Pfizer's in New York City after the 2009 merger.

Pharmaceutical fraud involves activities that result in false claims to insurers or programs such as Medicare in the United States or equivalent state programs for financial gain to a pharmaceutical company. There are several different schemes used to defraud the health care system which are particular to the pharmaceutical industry. These include: Good Manufacturing Practice (GMP) Violations, Off Label Marketing, Best Price Fraud, CME Fraud, Medicaid Price Reporting, and Manufactured Compound Drugs. Examples of fraud cases include the GlaxoSmithKline $3 billion settlement, Pfizer $2.3 billion settlement, and Merck $650 million settlement. Damages from fraud can be recovered by use of the False Claims Act, most commonly under the qui tam provisions which rewards an individual for being a "whistleblower", or relator (law).

<span class="mw-page-title-main">Study 329</span> Scientific article

Study 329 was a clinical trial which was conducted in North America from 1994 to 1998 to study the efficacy of paroxetine, an SSRI anti-depressant, in treating 12- to 18-year-olds diagnosed with major depressive disorder. Led by Martin Keller, then professor of psychiatry at Brown University, and funded by the British pharmaceutical company SmithKline Beecham—known since 2000 as GlaxoSmithKline (GSK)—the study compared paroxetine with imipramine, a tricyclic antidepressant, and placebo. SmithKline Beecham had released paroxetine in 1991, marketing it as Paxil in North America and Seroxat in the UK. The drug attracted sales of $11.7 billion in the United States alone from 1997 to 2006, including $2.12 billion in 2002, the year before it lost its patent.

References

  1. "MAJOR PHARMACEUTICAL FIRM CONCEALED DRUG INFORMATION". ag.ny.gov. 2010-03-27. Archived from the original on 2010-03-27. Retrieved 2020-12-27.
  2. "Side Effects by Alison Bass". PopMatters. 2 July 2008. Retrieved 2020-12-27.
  3. Weinberg, Steve (2008-07-25). "'Side Effects' humanizes antidepressant debate". USATODAY.com. Retrieved 2020-12-27.
  4. Friedman, Richard A. (2009-03-05). "Side Effects: A Prosecutor, a Whistleblower, and a Bestselling Antidepressant on Trial". The New England Journal of Medicine. 358 (26). doi:10.1056/NEJMbkrev0803656. Archived from the original on 2009-03-05. Retrieved 2020-12-27.
  5. "Science in Society Journalism Award winners". Archived from the original on 2009-09-15. Retrieved 2010-03-06.